Compare D R Horton Inc (DHI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Pfizer Inc — how do they compare? D R Horton Inc trades at $134.63 (market cap $37.99B), while Pfizer Inc trades at $27.95 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 4.2× D R Horton Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Pfizer Inc for 158 Days on average.
| DHI | PFE | |
|---|---|---|
Market Cap | $37.99B | $158.56B |
Volume | 2,974,460 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $29.02 |
52-Week Low | $132.53 | $23.67 |
Typical Hold Time | 46 Days | 158 Days |
Enterprise Value | $43.09B | $210.06B |
Dividend Yield | 1.33% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $133.28, down 2.54% on the day amid broader housing sector weakness. The stock shows bearish technical signals with oversold RSI conditions, while fundamentals remain solid with consistent earnings beats and attractive valuation multiples. Recent news highlights pressure from rising mortgage rates and housing market concerns, though the company maintains strong operational cash flow and analyst support.
DHI presents a value opportunity with below-market P/E of 12.95 and 47% analyst buy ratings, but faces headwinds from potential 9% mortgage rates and declining home sales. The consensus price target of $156.57 offers 17% upside, though investors should monitor Q3 2026 earnings on October 29 for margin sustainability.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
